痛结宁胶囊治疗乳腺增生病的临床疗效观察

目的 :评价痛结宁胶囊治疗乳腺增生病的临床疗效。方法 :30 0例乳腺增生病病人随机分成两组。治疗组 2 4 0例 ,口服痛结宁胶囊 ,每次 3粒 ,1日 3次。对照组 60例 ,口服维生素 E,1 0 0 mg,1日 1次。疗程 3个月。用 Ridit检验分析疗效。结果 :治疗组治愈率 2 1 .67% ,总有效率 88.75 % ;对照组治愈率 1 1 .67% ,总有效率 46.67% ,治疗组疗效明显优于对照组 ( P<0 .0 1 )。结论 :痛结宁治疗乳腺增生病有较好的疗效 ,病程越短 ,疗效越好 ,延长治疗时间可以提高治疗效果     

脑肿瘤患者手术前后T细胞亚群及NK细胞活性的变化

目的 探讨脑肿瘤患者手术前后细胞免疫功能的变化及其临床意义。方法 采用单克隆抗体酶标法对22例脑肿瘤和12例脑内血肿患者手术前后不同时期的T细胞亚群及NK细胞活性进行动态监测。结果 脑肿瘤CD3^ 、CD4^ ,CD10^16 56和CD4^ /CD8^ 比值较对照组均有不同程度降低。而胶质瘤组较其余两组明显下降。34例患者术后4期CD3^ ,CD4^ ,CD16 56^ 比值均发生变化。胶质瘤组在术后1至2周明显低于其余两组。术后3至4周才逐渐恢复至正常水平。结论 脑肿瘤患者细胞免疫功能被抑制。且恶性胶质瘤较良性肿瘤更为明显，手术应激能导致T细胞亚群及NK细胞活性变化。脑肿瘤切除术后细胞免疫功能呈现暂时抑制至逐渐恢复的过程。     

凝血栓蛋白1基因异常甲基化与大肠腺癌关联

目的 探讨凝血栓蛋白l（THBS1）基因启动子CpG岛异常甲基化与大肠腺癌及其临床病理特征的关联。方法 THBS1基因甲基化状态用甲基化特异性PCR检测。结果 大肠腺癌、癌旁组织中，THBSI基因启动子cpG岛甲基化率的差异有显著性（X^2=5．93，P=0．025）；老年患者肿瘤组织中THBS1基因甲基化率明显商于非老年患者（X^2=5.68，P=0．017），直径≥3cm的肿瘤组织中THBSl基因甲基化率显著高于直径〈3cm的肿瘤（X^2=4．16，P=0．041），C期和D期肿瘤组织中THBS1基因甲基化率显著高于A期或B期肿瘤（X^2=8．04，u=2，P=0．018）。结论 THBS1基因甲基化与大肠腺癌的发生有关，肿瘤以老年、晚期和直径较大的肿瘤多见。     

Distribution of alpha 2-adrenergic receptor mRNAs in the rat CNS.

alpha 2-Adrenergic receptors (ARs) are involved in central nervous system (CNS) control of blood pressure. It is now known that there are three human genes that encode subtypes of alpha 2-ARs, but little is known regarding the distribution of these subtypes throughout the CNS. The availability of receptor clones allows the mapping of mRNAs encoding the individual alpha 2-AR subtypes in the CNS. In this communication, we report that there are three, closely related rat alpha 2-AR genes. We have developed subtype-specific hybridization probes from each of these genes and have used these reagents to measure alpha 2-AR subtype mRNA accumulation in extracts of discrete regions of the rat CNS. We found that mRNAs encoding the alpha 2A-AR and alpha 2C-AR subtypes are distributed widely, but unevenly, throughout the rat CNS. The A subtype is prominent in the midbrain, brainstem, spinal cord, pituitary and diencephalon while the C subtype predominates in basal ganglia and cerebellum. The cortex, olfactory bulb and hippocampus contain roughly equal amounts of the alpha 2A- and alpha 2C-AR mRNAs. A third subtype's (alpha 2B-AR) mRNA is far less abundant in brain tissues, and is only found in the diencephalon.     

Poncet病(病例报告及文献复习)

目的 探讨Poncet病的诊断与治疗。方法 通过病例报告及献复习，综述了Poncet病的发病机理、临床表现。结果 提高对Poncet病的认识。结论 临床上对风湿性或类风湿性关节炎病人均应与本病鉴别。     

普拉固和鱼油对高胆固醇血症患者血脂与心脑血管事件影响的比较

目的:比较普拉固和鱼油对高胆固醇血症患者的血脂、血粘度、血管内皮功能和心脑血管事件的影响。方法:对266例原发性高胆固醇血症患者经2周洗脱期后,随机分为两组,普拉固组,初服10mg,每晚一次,8周后若TC仍>5.2mmol/L,LDL—ch>3.12mmol/L,则加量至20mg/d,每8周再查血脂,以达到TC<5.2mmol/L,LDL—ch<3.12mmol/L的量作治疗量继续服用。鱼油组,服美国深海鱼油一日三次,一次3g,均于服药8周复查血脂、血粘度及血管内皮功能等并作16月随访。结果:治疗8周,TC,普拉固组下降26％,鱼油组下降12％(P<0.01)。LDL—ch,普拉固组下降31％,鱼油组下降11％(P<0.01),肱动脉流量介导的舒张与硝酸甘油介导的舒张,普拉固组分别增加104％和19％,鱼油组无明显改变。全血低切粘度,普拉固组减少23％,鱼油组减少10％(P<0.01)。平均随访16月,普拉固组中脑出血1例(0.8％),鱼油组发生心脑血管事件7例(5.3％),死亡1例(P<0.05)。两组均无明显的不良反应。结论:普拉固是一个安全有效的降脂药,能改善血管内皮功能,降低血粘度,减少高胆固醇血症病人心脑血管事件发生。     

坏宜性脓皮病12例临床分析

报告12例疸性腔皮病患者的性别与年龄构成、并发症、实验室检查、治疗经过和结果，对该病的病因、治疗和预后进行了讨论。     

中西医结合冲击治疗免疫性不孕的临床研究

目的：探讨中西医结合冲击治疗对女性免疫性不孕症病人的治疗效果。方法：应用酶联免疫吸附法（ELISA）对560例病人血清和宫颈粘液中的抗精子抗体（AsAb）、抗子宫内膜抗体（IAEmAb）、抗卵巢抗体（AOVAb、抗人绒毛膜促性腺激素抗体（AhCGAb）进行检测，采用中药，维生素E、维生素C对所有抗体阳性者进行周期性治疗，2个周期为1疗程。结果：560例病人血清中共检测中各种抗体641例例次，宫颈粘液中共检出各抗体596例次。治疗1疗程，AsAb、AEmAb、AOVAb、AhCGAb在血清的转阴率分别为87．4％、85．4％、74．0％、86．5％，在宫颈粘液中的转阴率分别为93．7％、95．0％、87．0％，94．2％，在宫内颈粘液中的转阴率分别为90．1％、94．0％、94．7％、100．0％，抗体转阴后妊娠率高达58．2％，结论：中西医结合冲击治疗对免疫性不孕抗体转阴所需时间短，转阴率和转阴后妊娠率高，对AsAb、AEmAb、AOVAb与AhCGAb等所致的免疫性不孕均有显著疗效。     

组织多肽特异性抗原在原发性肝癌中的临床应用

OBJECTIVE: To evaluate the clinical value of serum tissue polypeptide specific antigen (TPS) for primary hepatic cancer in comparison with alpha-fetoprotein (AFP). METHODS: TPS and AFP were measured by enzyme-linked immunosorbent assay (ELISA) in 85 patients with primary hepatic cancer, 19 with metastatic hepatic cancer, 35 with liver cirrhosis, 22 with chronic hepatitis and 50 healthy control subjects. RESULTS: Serum AFP levels were elevated in patients with hepatocellular carcinoma in comparison with that in cholangiocarcinoma patients (P=0.037), but the difference was not significant (P=0.737). Serum TPS levels were significantly correlated with the tumor size (P=0.001), but not with the number of the tumors, portal invasion, extrahepatic metastasis, clinical stage or histological differentiation (P>0.05). A significant correlation was observed between AFP level and tumor size (P=0.028), portal invasion(P=0.005), and histological differentiation (P=0.000). CONCLUSION: TPS alone offers no more clues than AFP for the diagnosis of primary hepatic cancer, though it can be helpful for the diagnosis of cholangiocarcinoma. It has only limited clinical utility as a marker for primary hepatic cancer.     

Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent.

A new micelle system formed from methoxy (polyethylene glycol)-b-poly (5-benzyloxy-trimethylene carbonate; MePEG-b-PBTMC 5000-b-4800) was investigated as a delivery system for the hydrophobic anti-cancer agent, ellipticine. The ellipticine was loaded into the MePEG-b-PBTMC micelles with a loading efficiency of 95% using a high-pressure extrusion technique. The ellipticine-loaded micelles have a spherical morphology and an average diameter of 96 nm. The anti-cancer activity of ellipticine was confirmed to be retained following formulation in the MePEG-b-PBTMC micelles. The extent of protein adsorption to the MePEG-b-PBTMC micelles was investigated by transmission electron microscopy, dynamic light scattering and gel filtration chromatography. Overall, the amount of protein both loosely and tightly associated with the micelles was found to be minimal and insignificant. The partitioning properties of ellipticine between an aqueous medium containing protein and the MePEG-b-PBTMC micelles were examined over a range of protein concentrations. Under physiologically relevant conditions, it was found that 61% of the drug remained within the micelle fraction while 39% was in the protein-containing aqueous phase. In addition, the in vitro drug release profile of ellipticine from the micelles was fit using a modified Higuchi model and found to be accelerated in the presence of protein. These studies demonstrate that although there are no significant interactions between micelle and protein, the properties of the micelle as a delivery vehicle may be strongly influenced by protein-drug interactions.